|
WO2019173505A1
|
|
Methods of treating disorders related to glycemic control
|
|
WO2019118612A1
|
|
Targeting compounds
|
|
WO2018148652A1
|
|
Methods for identifying metap-2 modulators
|
|
US2018042886A1
|
|
Methods of treating age related disorders
|
|
US2019169181A1
|
|
Fumagillol compounds and methods of making and using same
|
|
MX2018001733A
|
|
Fumagillol heterocyclic compounds and methods of making and using same.
|
|
TW201613572A
|
|
Formulations having a METAP-2 inhibitor
|
|
US2015150857A1
|
|
Methods of treating an overweight or obese subject
|
|
CA2904353A1
|
|
Methods of treating renal disease and other disorders
|
|
MX2015005734A
|
|
Methods of treating liver diseases.
|
|
WO2014071363A1
|
|
Tricyclic compounds and methods of making and using same
|
|
CN104363905A
|
|
Treating hypothalamic obesity with metap2 inhibitors
|
|
CN104364251A
|
|
Fumigillol type compounds and methods of making and using same
|
|
US2015111964A1
|
|
Polymorphic salt of a metap-2 inhibitor and methods of making and using same
|
|
CA2861381A1
|
|
Tricyclic sulfone compounds and methods of making and using same
|
|
EP2804866A1
|
|
Tricyclic sulfonamide compounds and methods of making and using same
|
|
EP2763671A2
|
|
Methods of treating age related disorders
|
|
CA2835209A1
|
|
Tricyclic pyrazole sulfonamide compounds and methods of making and using same
|
|
NZ617388A
|
|
Partially saturated tricyclic compounds and methods of making and using same
|
|
EP2705036A1
|
|
Tricyclic sulfonamide compounds and methods of making and using same
|
